Target species
Dogs.
Indications for use for each target species
For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs. The veterinary medicinal product can also be used in the management of post-operative pain.
Contraindications
Do not exceed the stated dose.
The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. In the absence of specific data use of the veterinary medicinal product in the cat is contra-indicated.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of blood dyscrasia or hypersensitivity to the product.
Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Special warnings
None.
Special precautions for use
Special precautions for safe use in the target species:
Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential rise of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
NSAID’s can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after handling the product.
Special precautions for the protection of the environment:
Not applicable.
Adverse events
Dogs:
Rare (1 to 10 animals / 10,000 animals treated): | Gastric ulceration, Intestinal disorder1 Hepatic disorder2 Renal disorder2 |
Very rare (< 1 animal / 10,000 animals treated, including isolated reports): | Blood in faeces3, Diarrhoea3, Vomiting3 Appetite loss3, Lethargy3 |
1 Reported as ulceration.
2 As with any other NSAIDs. Reported as idiosyncrasy.
3 Typical undesirable effects associated with NSAIDs that generally occur within the first treatment week and are in most cases transient and disappear following termination of treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped, and the advice of a veterinarian should be sought.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy:
The use is not recommended during the pregnancy.
Interaction with other medicinal products and other forms of interaction
No significant drug interactions have been reported for carprofen. The acute toxicity of carprofen in animals was not significantly affected in tests with fifteen commonly used (or commonly available) drugs. These were acetylsalicylic acid, amphetamine, atropine, chlorpromazine, diazepam, diphenhydramine, ethyl alcohol, hydrochlorothiazide, imipramine, meperidine, propoxyphene, pentobarbital, sulfisoxazole, tetracycline and tolbutamide.
Whilst carprofen and warfarin may both be bound to plasma proteins; they may be used concurrently provided the clinical situation is carefully monitored since it has been shown that they bind to two distinct sites on human and bovine serum albumin.
Administration routes and dosage
Oral use.
The veterinary medicinal product is palatable and willingly consumed by most dogs when offered.
An initial dose of 2 to 4 mg carprofen per kg bodyweight per day is recommended to be given as a single dose or in two equally divided doses. Subject to clinical response, the dose may be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose.
To extend analgesic and anti-inflammatory cover post-operatively, parenteral therapy with Rimadyl Small Animal Injection may be followed with the tablets at 4mg/kg/day for up to 5 days.
Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAID’s, should be applied.
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
Withdrawal period
Not applicable.